8-K 1 v439253_8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 10, 2016

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

| Delaware |  | 99-0370688 |
| (State or other jurisdiction of incorporation) |  | (IRS Employer Identification Number) |

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 | Regulation FD Disclosures

The Company will be presenting materials regarding TLANDO™ (“LPCN 1021”) clinical data at the 2016 American Urological Association Meeting in San Diego, CA on May 10, 2016. The Company’s materials to be used in the presentation are attached hereto as Exhibit 99.1.

Item 9.01 | Financial Statements and Exhibits.

| (d) | Exhibits

The following exhibits are filed with this report:

Exhibit No. | Description
99.1 | Poster Concerning Long-term Safety and Tolerability of Oral Testosterone (LPCN 1021) in Hypogonadal Men: Results from the 52-Week Phase 3 Study

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  | LIPOCINE INC.
Date: | May 10, 2016 |  | By: | /s/ Mahesh V. Patel
|  |  |  | Mahesh V. Patel
|  |  |  | President and Chief Executive Officer